Related Experiment Videos
Antihistamines, a possible risk factor for Alzheimer's disease
Medical Hypotheses
|January 1, 1995
Summary
Many antihistamines, often given to psychiatric patients, may worsen or cause Alzheimer's disease. Researchers suggest limiting antihistamine use in all patients until the link between these drugs and Alzheimer's is better understood.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Antihistamines are commonly prescribed to psychiatric patients.
- Schizophrenia patients exhibit a high prevalence of Alzheimer's disease neuropathology.
- Neuroleptic medications, often used for schizophrenia, possess anticholinergic properties.
Purpose of the Study:
- To investigate the potential role of antihistamines and anticholinergic drugs in Alzheimer's disease.
- To explore the link between neuroleptic treatment and Alzheimer's neuropathology in schizophrenic patients.
Main Methods:
- Review of existing studies on schizophrenia, Alzheimer's disease, and neuroleptic medications.
- Analysis of the anticholinergic and antihistamine properties of commonly used psychotropic drugs.
Main Results:
- A significant association between neuroleptic treatment and increased Alzheimer's neuropathology in schizophrenics was observed.
- Many neuroleptics, including some antihistamines like chlorpromazine, have anticholinergic effects.
- Anticholinergic agents may exacerbate or contribute to the etiology/pathogenesis of Alzheimer's disease.
Conclusions:
- Anticholinergic drugs, including antihistamines, may negatively impact cerebral cholinergic systems.
- Prudent use of antihistamines is recommended for both psychiatric patients and the general population pending further research.
- The potential contribution of antihistamines to Alzheimer's disease warrants further investigation.